Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase 1 3Phase EARLY_PHASE1 1Phase 4 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 1

Interventions

Specimen Handling 3Magnetic Resonance Spectroscopy 3Cisplatin 3Letrozole 2Immune Checkpoint Inhibitors 2Imatinib Mesylate 2Human Papillomavirus Recombinant Vaccine nonavalent 2Diosmin 2Carboplatin 2Azacitidine 2venetoclax 1trametinib 1toripalimab 1tocilizumab 1sofosbuvir-velpatasvir drug combination 1semaglutide 1ruxolitinib 1rozanolixizumab 1rasburicase 1radium Ra 223 dichloride 1pyrotinib 1pirtobrutinib 1oxycodone-acetaminophen 1obinutuzumab 1nirogacestat 1niraparib 1nilotinib 1naldemedine 1idelalisib 1human papillomavirus vaccine, L1 type 16, 18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × enfortumab vedotin × 30 days × Clear all
NCT06862219 2026-05-28

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Astellas Pharma Inc

Phase 4 Recruiting
100 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡